Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model by R. Alvim et al.
Positron Emission Tomography/Computed Tomography with
Gallium-68-labeled Prostate-specific Membrane Antigen
Detects Relapse After Vascular-targeted Photodynamic
Therapy in a Prostate Cancer Model
Submitted by Stéphanie Pinot on Thu, 09/19/2019 - 12:10
Titre
Positron Emission Tomography/Computed Tomography with Gallium-68-labeled
Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted
Photodynamic Therapy in a Prostate Cancer Model
Type de
publication Article de revue
Auteur
Alvim, Ricardo [1], Nagar, Karan [2], Das, Sudeep [3], Lebdai, Souhil [4], Wong,
Nathan [5], Somma, Alexander J [6], Hughes, Christopher [7], Thomas, Jasmine [8],
Monette, Sebastien [9], Scherz, Avigdor [10], Kim, Kwanghee [11], Grimm, Jan [12],
Coleman, Jonathan A [13]
Editeur Elsevier
Type Article scientifique dans une revue à comité de lecture
Année 2019
Langue Anglais
Date 18 Juin 2019
Titre de la
revue European urology focus
ISSN 2405-4569
Résumé en
anglais
BACKGROUND: Evaluating the efficacy of focal therapy for prostate cancer is
limited by current approaches and may be improved with biological imaging
techniques.
OBJECTIVE: We assessed whether positron emission tomography/computed
tomography with gallium-68-labeled prostate-specific membrane antigen (Ga-PSMA
PET/CT) can be used to predict relapse after vascular-targeted photodynamic
therapy (VTP).
DESIGN, SETTING, AND PARTICIPANTS: A total of 1×10 LNCaP cells were grafted
subcutaneously in the flanks of 6-8-wk-old SCID mice. Of 24 mice with measurable
tumors 6 wk after tumor implantation, 20 were treated with VTP (150mW/cm) to
ablate the tumors. Blood prostate-specific antigen (PSA) levels were assessed, and
⁶⁸Ga-PSMA PET/CT images were performed 1 d before VTP and 1 and 4 wk after.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Local tumor relapse
was evaluated by histology, and tumors were analyzed by prostate-specific
membrane antigen (PSMA) and PSA immunohistochemistry. T tests and Kruskal-
Wallis tests were used to determine significance.
RESULTS AND LIMITATIONS: Four weeks after VTP, 11 (65%) mice had complete
responses and six (35%) had tumor relapses confirmed by histology (hematoxylin
and eosin, and PSMA immunohistochemistry). All mice with local relapse had
positive Ga-PSMA PET/CT findings 4 wk after VTP; all complete responders did not.
One week after VTP, the relapse detection sensitivity of Ga-PSMA PET/CT was 75%,
whereas the sensitivity of PSA was only 33%. Compared with controls, relapsed
tumors had a three-fold reduction in the number of cells with strong PSA staining by
immunohistochemistry (1.5% vs 4.5%; p=0.01).
CONCLUSIONS: In a preclinical prostate cancer model, we show that Ga-PSMA
PET/CT can identify and predict relapse earlier than blood PSA level. These findings
support further testing in clinical trials.
PATIENT SUMMARY: Positron emission tomography/computed tomography with
gallium-68-labeled prostate-specific membrane antigen may be used to follow and
evaluate treatment outcomes in men who receive focal therapy for prostate cancer.
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